Insight Molecular Diagnostics (IMDX) Equity Average (2016 - 2026)

Insight Molecular Diagnostics (IMDX) has 11 years of Equity Average data on file, last reported at -$21.1 million in Q1 2026.

• Quarterly Equity Average fell 1950.34% year-over-year to -$21.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$21.1 million (down 1950.34% YoY) and the FY2025 annual result came in at -$21.9 million, down 633.78% from the prior year.
• Equity Average declined to -$21.1 million in Q1 2026 per IMDX's latest filing, from -$20.3 million in the prior quarter.
• The five-year high for Equity Average was $80.0 million in Q3 2022, with the low at -$21.1 million in Q1 2026.
• Average Equity Average over 5 years is $24.7 million, with a median of $17.1 million recorded in 2024.
• Year-over-year, Equity Average retreated 12.79% in 2022 and sank 1950.34% in 2026.
• Insight Molecular Diagnostics' Equity Average stood at $55.6 million in 2022, then sank by 49.07% to $28.3 million in 2023, then sank by 104.53% to -$1.3 million in 2024, then plunged by 1486.42% to -$20.3 million in 2025, then slipped by 3.68% to -$21.1 million in 2026.
• Business Quant data shows IMDX's Equity Average at -$21.1 million in Q1 2026, -$20.3 million in Q4 2025, and -$4.0 million in Q3 2025.